Boehringer Ingelheim Biopharmaceuticals (China) Ltd.June 9, 2023

FDA 483 - Boehringer Ingelheim Biopharmaceuticals (China) Ltd. - June 09, 2023

FDA 483 for Boehringer Ingelheim Biopharmaceuticals (China) Ltd. on June 09, 2023. Product: drugs. Access full analysis and detailed observations.

View on Dashboard

One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.

Record Summary

FDA 483 for Boehringer Ingelheim Biopharmaceuticals (China) Ltd. on June 09, 2023. Product: drugs. Access full analysis and detailed observations.

Get More Insights

Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.

1.5M+ regulatory data points

Real-time compliance monitoring

Interactive analytics dashboard

Looking for more records? Our platform provides access to thousands of similar regulatory documents with advanced search and filtering capabilities.

Record Information

Company

Boehringer Ingelheim Biopharmaceuticals (China) Ltd.

Inspection Date

June 9, 2023

Product Type

drugs

Office

Division of Clinical Evidence and Analysis 1 (Clinical Policy and Quality)

People

ID: 043bec50-de87-4e6d-a9d9-e057770f067b

View on Dashboard

Transform Regulatory Data into Actionable Intelligence

Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.

Try KeyPedia Today

Explore our real use cases and discover our features in depth.

Subscribe to our newsletter

Get the latest updates and insights delivered to your inbox